Teva and Celltrion Reports the Availability of Truxima (biosimilar, Rituxan) in the US

Teva and Celltrion Reports the Availability of Truxima (biosimilar, Rituxan) in the US

Shots:

  • Teva and Celltrion launch Truxima (rituximab-abbs) injection as the first biosimilar referencing Roche’s Rituxan (rituximab) to be available in the US by the week of November 11, addressing the unmet medical needs of the patients in the US
  • The approval of Truxima is based on clinical/ nonclinical, pharmacology, immunogenicity, clinical efficacy and safety data. Truxima is being made available via primary wholesalers at a WAC of $845.55 for 100mg vial and $4227.75 for 500mg vial with its actual cost to be lower than WAC
  • Truxima is the first rituximab biosimilar and has received FDA’s approval to match all the reference product’s oncology indications for NHL and CLL in May’2019. Additionally, Celltrion and Teva have a pending submission of Truxima for RA, GPA, & MPA with a license to expand its label to include these indications in Q2’20

Click here to­ read full press release/ article | Ref: Businesswire | Image: Reuters